Efstathios Kastritis, MD

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

The expert discussed key details from the phase 3 ANDROMEDA trial presented at the 2021 ASCO Annual Meeting.

The phase 3 ANDROMEDA trial demonstrated positive efficacy and safety data in the treatment of newly diagnosed light chain amyloidosis.

To define the differences between the subtypes of myeloma patients, not only prospective collection of clinical and laboratory data are needed, but also cytogenetics and molecular profiling.